Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Stephen I. Rennard; Charles Fogarty; Steven Kelsen; William Long; Joe Ramsdell; James Allison; Donald Mahler; Constantine Saadeh; Thomas Siler; Phillip Snell; et al. (Profiled Author: James F Donohue)
American Journal of Respiratory and Critical Care Medicine. 2007;175(9):926-934.Abstract
Rationale: Chronic obstructive pulmonary disease (COPD) is a progressive, smoking-related, inflammatory lung disease in which tumor necrosis factor-α is overexpressed and has been suggested to play a pathogenic role. Objectives: To determine if infliximab, an anti-TNF-α antibody, results in clinical benefit and has an acceptable safety profile in patients with moderate to severe COPD. Methods: In a multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study, subjects with moderate to severe COPD received infliximab (3 mg/kg [n = 78] or 5 mg/kg [n = 79]) or placebo (n = 77) at Weeks 0, 2, 6, 12, 18, and 24. Efficacy, health status, and safety were assessed through Week 44. Measurements and Main Results: Infliximab was generally well tolerated, but showed no treatment benefit as measured by the primary endpoint, Chronic Respiratory Questionnaire total score. Similarly, there was no change in secondary measures, including prebronchodilator FEV1, 6-min walk distance, SF-36 physical score, transition dyspnea index, or moderate-to-severe COPD exacerbations. Post hoc analysis revealed that subjects who were younger or cachectic showed improvement in the 6-min walk distance. Malignancies were diagnosed during the study in 9 of 157 infliximab-treated subjects versus 1 of 77 placebo-treated subjects. No opportunistic infections were observed, and there were no differences in the occurrence of antibiotic-requiring infections, although the incidence of pneumonia was higher in infliximab-treated subjects. No infection-related mortality was observed. Higher proportions of infliximab-treated subjects discontinued the study agent due to adverse events (20-27%) than did placebo-treated subjects (9%). Conclusions: Subjects with moderate to severe COPD did not benefit from treatment with infliximab. Although not statistically significant, more cases of cancer and pneumonia were observed in the infliximab-treated subjects. The impact of infliximab on malignancy risk in patients with COPD needs to be further elucidated.
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Robyn J. Barst; Michael McGoon; Vallerie McLaughlin; Victor Tapson; Ronald Oudiz; Shelley Shapiro; Ivan M. Robbins; Richard Channick; David Badesch; Barry K. Rayburn; et al.Journal of the American College of Cardiology. 2003;41(12):2119-2125.
James F Donohue; Jill A OharProc Am Thorac Soc. 2004;1(3):152-160.
William J. Sandborn; Jean-Frédéric Colombel; Stefan Schreiber; Scott E. Plevy; Paul F. Pollack; Anne M. Robinson; Jingdong Chao; Parvez MulaniInflammatory Bowel Diseases. 2011;17(1):141-151.
Appears in this Document